A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

Gynecologic cancers are traditionally managed according to their presumed site of origin, without regard to the underlying histologic subtype. Clear cell histology is associated with chemotherapy refractoriness and poor survival. Mutations in SWI/SNF chromatin remodeling complex member ARID1A, which...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2023-09, Vol.176, p.16-24
Hauptverfasser:	O'Cearbhaill, Roisin E., Miller, Austin, Soslow, Robert A., Lankes, Heather A., DeLair, Deborah, Segura, Sheila, Chavan, Shweta, Zamarin, Dmitriy, DeBernardo, Robert, Moore, Kathleen, Moroney, John, Shahin, Mark, Thaker, Premal H., Wahner-Hendrickson, Andrea E., Aghajanian, Carol
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma, Clear Cell - drug therapy Adenocarcinoma, Clear Cell - genetics Adenocarcinoma, Clear Cell - metabolism ARID1A mutation BAF250a Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - genetics Carcinoma, Endometrioid - metabolism Clear cell cancer Dasatinib Dasatinib - adverse effects Endometrium - pathology Fallopian Tubes - pathology Female Humans Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - metabolism Peritoneum - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!